Your browser doesn't support javascript.
loading
Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study.
Yonemori, Kan; Kuboki, Yasutoshi; Hasegawa, Kosei; Iwata, Takashi; Kato, Hidenori; Takehara, Kazuhiro; Hirashima, Yasuyuki; Kato, Hisamori; Passey, Chaitali; Buchbjerg, Jeppe Klint; Harris, Jeffrey R; Andreassen, Camilla Mondrup; Nicacio, Leonardo; Soumaoro, Ibrahima; Fujiwara, Keiichi.
Affiliation
  • Yonemori K; National Cancer Center Hospital, Tokyo, Japan.
  • Kuboki Y; National Cancer Center Hospital East, Chiba, Japan.
  • Hasegawa K; Saitama Medical University International Medical Center, Saitama, Japan.
  • Iwata T; Keio University School of Medicine, Tokyo, Japan.
  • Kato H; National Hospital Organization, Hokkaido Cancer Center, Sapporo, Japan.
  • Takehara K; NHO Shikoku Cancer Center, Matsuyama, Japan.
  • Hirashima Y; Shizuoka Cancer Center, Shizuoka, Japan.
  • Kato H; Kanagawa Cancer Center, Kanagawa, Japan.
  • Passey C; Genmab US, Inc., Princeton, New Jersey, USA.
  • Buchbjerg JK; Genmab A/S, Copenhagen, Denmark.
  • Harris JR; Genmab US, Inc., Princeton, New Jersey, USA.
  • Andreassen CM; Genmab A/S, Copenhagen, Denmark.
  • Nicacio L; Seagen Inc., Bothell, WA, USA.
  • Soumaoro I; Genmab US, Inc., Princeton, New Jersey, USA.
  • Fujiwara K; Saitama Medical University International Medical Center, Saitama, Japan.
Cancer Sci ; 113(8): 2788-2797, 2022 Aug.
Article in En | MEDLINE | ID: mdl-35633184
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Immunoconjugates Limits: Female / Humans Language: En Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Immunoconjugates Limits: Female / Humans Language: En Year: 2022 Type: Article